Legal & General Group Plc increased its holdings in shares of CryoLife, Inc. (NYSE:CRY) by 8.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 50,224 shares of the medical equipment provider’s stock after acquiring an additional 4,049 shares during the quarter. Legal & General Group Plc owned about 0.15% of CryoLife worth $1,002,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of CRY. Municipal Employees Retirement System of Michigan increased its holdings in shares of CryoLife by 3.2% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock worth $102,000 after acquiring an additional 190 shares during the last quarter. Mason Street Advisors LLC increased its holdings in shares of CryoLife by 7.4% during the 1st quarter. Mason Street Advisors LLC now owns 6,324 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 438 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in shares of CryoLife by 80.8% during the 2nd quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock worth $107,000 after acquiring an additional 2,407 shares during the last quarter. First Mercantile Trust Co. increased its holdings in shares of CryoLife by 5.6% during the 2nd quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock worth $109,000 after acquiring an additional 291 shares during the last quarter. Finally, Creative Planning increased its holdings in shares of CryoLife by 3.0% during the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after acquiring an additional 200 shares during the last quarter. 68.44% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/cryolife-inc-cry-position-lifted-by-legal-general-group-plc/1600120.html.

CRY has been the topic of a number of recent analyst reports. Zacks Investment Research raised CryoLife from a “sell” rating to a “hold” rating in a report on Monday, August 14th. BidaskClub lowered CryoLife from a “buy” rating to a “hold” rating in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $22.00.

In other CryoLife news, CEO James P. Mackin sold 43,050 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $22.09, for a total value of $950,974.50. Following the completion of the sale, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at $8,800,633.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James P. Mackin sold 125,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total value of $2,751,250.00. Following the completion of the sale, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at $8,768,761.99. The disclosure for this sale can be found here. Insiders sold 169,050 shares of company stock valued at $3,724,225 over the last three months. Company insiders own 6.00% of the company’s stock.

CryoLife, Inc. (NYSE CRY) opened at 22.70 on Friday. CryoLife, Inc. has a one year low of $14.03 and a one year high of $23.35. The firm has a 50-day moving average price of $20.14 and a 200-day moving average price of $18.49. The firm has a market capitalization of $759.22 million, a price-to-earnings ratio of 68.79 and a beta of 0.97.

CryoLife (NYSE:CRY) last released its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.02. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The business had revenue of $47.80 million during the quarter, compared to the consensus estimate of $47.02 million. During the same period last year, the business posted $0.13 earnings per share. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. Analysts expect that CryoLife, Inc. will post $0.43 EPS for the current year.

CryoLife Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoLife, Inc. (NYSE:CRY).

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.